KRON Stock Overview
A clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Kronos Bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.90 |
| 52 Week High | US$1.60 |
| 52 Week Low | US$0.69 |
| Beta | 1.86 |
| 11 Month Change | -6.91% |
| 3 Month Change | -9.54% |
| 1 Year Change | -28.90% |
| 33 Year Change | -92.20% |
| 5 Year Change | n/a |
| Change since IPO | -96.66% |
Recent News & Updates
Recent updates
Shareholders Will Probably Hold Off On Increasing Kronos Bio, Inc.'s (NASDAQ:KRON) CEO Compensation For The Time Being
Jun 20
Is Kronos Bio (NASDAQ:KRON) In A Good Position To Deliver On Growth Plans?
Jun 11Kronos Bio: Still Promising But Riskier Following ASCO Update
Jun 05Kronos Bio: Underestimated Drug Discovery Platform
May 06Is Kronos Bio (NASDAQ:KRON) In A Good Position To Invest In Growth?
Jan 19We're Keeping An Eye On Kronos Bio's (NASDAQ:KRON) Cash Burn Rate
Aug 21We Think Kronos Bio (NASDAQ:KRON) Needs To Drive Business Growth Carefully
Feb 22Is Kronos Bio (NASDAQ:KRON) In A Good Position To Deliver On Growth Plans?
Nov 01Kronos Bio, Invivoscribe to develop companion diagnostic for leukemia drug entospletinib
Aug 16Is Kronos Bio (NASDAQ:KRON) In A Good Position To Invest In Growth?
Jul 07We're Hopeful That Kronos Bio (NASDAQ:KRON) Will Use Its Cash Wisely
Feb 01How Much Of Kronos Bio, Inc. (NASDAQ:KRON) Do Insiders Own?
Mar 03Read This Before Selling Kronos Bio, Inc. (NASDAQ:KRON) Shares
Jan 09
Kronos Bio EPS misses by $4.10
Nov 18Shareholder Returns
| KRON | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 6.2% | 2.5% | 2.2% |
| 1Y | -28.9% | 16.1% | 31.6% |
Return vs Industry: KRON underperformed the US Biotechs industry which returned 16.1% over the past year.
Return vs Market: KRON underperformed the US Market which returned 31.6% over the past year.
Price Volatility
| KRON volatility | |
|---|---|
| KRON Average Weekly Movement | 7.6% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: KRON has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: KRON's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 58 | Norbert Bischofberger | www.kronosbio.com |
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California.
Kronos Bio, Inc. Fundamentals Summary
| KRON fundamental statistics | |
|---|---|
| Market cap | US$54.49m |
| Earnings (TTM) | -US$85.59m |
| Revenue (TTM) | US$9.86m |
5.5x
P/S Ratio-0.6x
P/E RatioIs KRON overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KRON income statement (TTM) | |
|---|---|
| Revenue | US$9.86m |
| Cost of Revenue | US$0 |
| Gross Profit | US$9.86m |
| Other Expenses | US$95.45m |
| Earnings | -US$85.59m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.42 |
| Gross Margin | 100.00% |
| Net Profit Margin | -867.66% |
| Debt/Equity Ratio | 0% |
How did KRON perform over the long term?
See historical performance and comparison